

1 **Supplementary data**

2

3 **for article “Metabotyping Patients’ Journeys Reveals Early Predisposition to Lung Injury after**
4 **Cardiac Surgery”**

5

6 Raluca Georgiana Maltesen, Bodil Steen Rasmussen, Shona Pedersen, Munsoor Ali Hanifa, Sergey
7 Kucheryavskiy, Søren Risom Kristensen, Reinhard Wimmer

8

9 **Table S1 A prolonged surgical procedure affects the metabolome.** *Association between metabolome and duration of*
10 *surgical procedure assessed by partial least square (PLS) regression. Both the calibrated (Cal) and cross-validated (CV)*
11 *results are provided. At 4 hours post-CPB the association was weaker, suggesting that the metabolome had begun*
12 *normalizing after prolonged surgical stress. No significant CV association was observed at 8 and 20 hours postoperatively.*
13 *Models with low predicted association are marked in grey.*

	CABG (196 ± 50 min.)		CPB (64 ± 29 min.)		Ischemia (33±19 min.)	
	R ² Cal	R ² CV	R ² Cal	R ² CV	R ² Cal	R ² CV
0 hour	-	-	0.94	0.76	0.92	0.75
2 hours	0.9	0.75	0.87	0.67	0.72	0.54
4 hours	0.82	0.6	0.7	0.41	0.7	0.44
8 hours	0.68	0.44	0.7	0.36	0.61	0.41
20 hours	0.74	0.39	0.55	0.32	0.63	0.38

14

15

16 **Table S2 Metabolite time profiles in both left atrium (LA) and pulmonary artery (PA) samples.** Mean change in
 17 percentage was calculated using the formula: $(\text{post-CPB} - \text{pre-CPB})/\text{pre-CPB} * 100$. Significance was assessed by means of
 18 factorial ANOVA with Tukey's post hoc test for multiple comparisons. Abbreviations: TMAO, trimethylamine-N-oxide; N-
 19 Ac-Gal, N-acetyl-galactosamine; N-Ac-Glc, N-acetyl-glucosamine; FA, fatty acids; MUFA, monounsaturated fatty acids;
 20 PUFA, polyunsaturated fatty acids; DAG, diacylglycerol; PEP, phosphoenolpyruvate; 4.60ppm*, unassigned metabolite;
 21 DAGPL, diacylglycerophosphocholine; PC, phosphatidylcholine; GPC, glycerophosphocholine; SM, sphingomyelin.

Metabolites	0 hour		2 hours		4 hours		8 hours		20 hours		p-value	
	LA	PA	LA	PA	LA	PA	LA	PA	LA	PA	LA	PA
Trigonelline	-15	-17	-32	-38	-45	-46	-50	-53	-49	-63	0.010	0.001
Formate	2	1	-13	-15	-20	-20	-19	-21	-16	-14	<0.0001	<0.0001
Inosine	-14	-18	-27	-25	-28	-29	-24	-25	-24	-30	<0.0001	<0.0001
Hypoxanthine	-13	-12	-6	-4	-9	-7	4	0	12	8	<0.0001	<0.0001
Adenine	6	12	56	45	51	47	67	67	65	54	<0.0001	<0.0001
Tryptophan	-25	-22	-29	-28	-28	-27	-19	-22	-10	-10	<0.0001	<0.0001
Histidine	-1	-1	-9	-11	-14	-15	-13	-14	-14	-16	<0.0001	<0.0001
3-Methylhistidine	4	4	11	9	6	6	14	15	36	32	<0.0001	<0.0001
1- Methylhistidine	-7	-10	-7	-11	-12	-14	-5	-9	6	0	<0.0001	<0.0001
Phenylalanine	4	4	1	-1	1	-1	-4	-6	8	6	0.03	0.02
Uric acid	-6	-8	-13	-17	-13	-16	-2	-6	24	17	<0.0001	<0.0001
Tyrosine	4	3	-13	-15	-15	-16	-18	-19	-13	-16	<0.0001	<0.0001
Glucuronate	5	6	15	13	9	9	30	26	100	94	<0.0001	<0.0001
Xanthine	-16	-16	-26	-26	-24	-25	-14	-16	5	3	<0.0001	<0.0001
L-Dopa	0	-1	-8	-10	-11	-12	-11	-12	-7	-9	<0.0001	<0.0001
Fumarate	2	1	-11	-13	-9	-9	7	-1	8	3	0.04	0.21
Uridine	4	3	-5	-7	-9	-9	-14	-15	-23	-28	<0.0001	<0.0001
Urea	3	1	4	1	5	4	-4	-6	-24	-27	<0.0001	<0.0001
MUFA	-25	-25	49	46	77	76	76	75	63	59	<0.0001	<0.0001
TAG	-7	-9	123	123	159	162	146	147	136	134	<0.0001	<0.0001

N-Ac-Glc	5	4	17	16	26	27	41	41	60	59	<0.0001	<0.0001
DAG	15	13	6	8	4	6	12	12	19	14	0.001	0.02
PEP	10	7	22	20	30	30	16	15	-21	-21	<0.0001	<0.0001
N-Ac-Gal	16	21	15	13	13	18	-22	-23	-61	-56	<0.0001	<0.0001
β -Glucose	38	39	15	14	11	12	17	17	13	13	<0.0001	<0.0001
4.60 ppm*	-27	-25	-24	-27	-18	-20	-8	-12	27	31	<0.0001	<0.0001
Malic acid	-7	-3	-31	-33	-39	-39	-39	-39	-41	-37	<0.0001	<0.0001
Ascorbate	2	10	-27	-28	-27	-28	-21	-22	-19	-9	<0.0001	<0.0001
DAGPL	-25	-19	-46	-48	-47	-48	-41	-43	-22	-16	<0.0001	<0.0001
PC	-18	-17	-3	-6	2	1	-1	-3	1	1	<0.0001	<0.0001
GPC	-7	-7	-14	-16	-14	-17	-14	-16	-10	-11	<0.0001	<0.0001
Lactate	36	33	5	0	6	2	-1	-4	-7	-11	<0.0001	<0.0001
Glycerol	11	10	26	20	34	32	1	-1	-45	-46	<0.0001	<0.0001
Glycine	-3	-4	-7	-11	-12	-13	-20	-21	-30	-33	<0.0001	<0.0001
α -Glucose	36	36	16	14	12	13	18	18	12	11	<0.0001	<0.0001
Taurine	-1	-2	-10	-11	-14	-13	-17	-17	-25	-26	<0.0001	<0.0001
Choline, SM	-17	-18	-9	-10	-3	-4	3	2	1	1	<0.0001	<0.0001
TMAO	-4	-5	-10	-12	-14	-14	-15	-16	-18	-21	0.03	0.007
Malonate	-1	-2	-4	-6	-7	-6	-8	-7	-7	-8	0.80	0.81
Creatinine	-2	-2	-3	-3	-4	-4	-4	-4	-5	-6	0.09	0.04
Creatine	31	33	29	26	19	23	15	12	8	9	<0.0001	<0.0001
Lipoic acid	-5	-5	-15	-17	-39	-38	-58	-59	-72	-72	<0.0001	<0.0001
PUFA	-27	-27	38	35	60	59	62	61	59	58	<0.0001	<0.0001
Citrate	28	30	27	25	41	41	22	22	2	2	0.01	0.01
Glutamine	-1	-1	-17	-18	-24	-24	-24	-24	-26	-28	<0.0001	<0.0001
Pyruvate	67	61	36	29	38	35	32	28	41	33	<0.0001	<0.0001

Glutamate	1	0	-2	-3	-4	-5	-7	-7	-5	-6	0.21	0.15
3-HBA	-17	-17	-19	-20	-14	-15	-5	-6	-13	-14	0.007	0.003
Acetoacetic acid	-23	-23	-8	-8	0	1	9	8	-25	-26	0.02	0.02
Acetone	5	-1	108	96	139	132	146	134	97	87	<0.0001	<0.0001
Acetate	-18	-20	-37	-39	-44	-44	-48	-48	-74	-74	<0.0001	<0.0001
Lysine	-3	-3	-9	-11	-18	-19	-23	-24	-30	-32	<0.0001	<0.0001
Proline	-3	-3	-10	-11	-18	-18	-22	-23	-24	-26	<0.0001	<0.0001
Arginine	-6	-6	-9	-10	-20	-20	-30	-31	-39	-39	<0.0001	<0.0001
Free FA	-29	-30	221	206	266	260	226	219	222	208	<0.0001	<0.0001
Alanine	16	15	-3	-6	-11	-11	-10	-10	-10	-13	<0.0001	<0.0001
Ethanol	-45	-46	-31	-35	-34	-32	-35	-34	-36	-35	<0.0001	<0.0001
Isobutyrylglycine	-12	-13	-29	-30	-42	-42	-55	-55	-70	-71	<0.0001	<0.0001
Isobutyrate & Carnitine	-7	-7	-9	-11	-16	-18	-31	-32	-41	-42	<0.0001	<0.0001
Valine	-3	-3	-9	-11	-18	-17	-25	-26	-33	-35	<0.0001	<0.0001
Isoleucine	-14	-14	-28	-30	-39	-39	-44	-44	-33	-35	<0.0001	<0.0001
Leucine	-7	-8	-5	-7	-8	-9	-11	-13	-11	-14	0.004	0.000
Lipoprotein	-30	-30	30	28	52	52	60	58	64	60	<0.0001	<0.0001
Total Cholesterol	-32	-35	1	0	20	18	33	30	38	28	<0.0001	<0.0001

22

23

24

25 **Table S3 Early prediction of hypoxaemia.** *Partial least squares (PLS) regression and partial least squares –discriminant*
 26 *analysis (PLS-DA) results. The results show both the calibrated (Cal) and Venetian-Blinds cross-validated (CV) coefficient*
 27 *of association (R^2), specificity, sensitivity, and class error. Each model was built on 100 samples collected from 50 patients*
 28 *from the left atrium and pulmonary artery at one of the mentioned time points. For validation, the Venetian-Blinds cross-*
 29 *validation with 10 segments was applied. 10 consecutive samples were removed and a model was created. Subsequently, the*
 30 *10 samples were predicted. This procedure was repeated until all samples were removed once. Permutation testing was*
 31 *applied for each model. A p-value ≤ 0.004 was considered significant.*

	PLS regression (Metabolome vs. PaO ₂)					PLS-DA (Metabolome vs. Outcome (hypoxaemia: yes/no))						
	R ²		RMSE		Permutation	Sensitivity		Specificity		Class error		Permutation
	Cal	CV	Cal	CV	p-value	Cal	CV	Cal	CV	Cal	CV	p-value
Pre-CPB	0.94	0.707	0.33	0.75	0.004	0.83	0.78	0.95	0.84	0.11	0.19	0.004
0 hour	0.98	0.918	0.15	0.4	<0.001	1	0.88	0.98	0.92	0.01	0.1	<0.001
2 hours	0.98	0.934	0.13	0.36	<0.001	1	0.91	0.98	0.94	0.01	0.1	<0.001
4 hours	0.98	0.954	0.12	0.3	<0.001	0.97	0.88	0.92	0.88	0.06	0.12	<0.001
8 hours	0.98	0.941	0.13	0.34	<0.001	0.97	0.94	0.97	0.92	0.03	0.07	<0.001
20 hours	0.98	0.903	0.19	0.44	<0.001	0.96	0.93	0.97	0.91	0.04	0.08	<0.001

32

33